About Chugai Pharmaceutical
Chugai Pharmaceutical is a publicly listed company based in Tokyo (Japan) founded in 1925, and was acquired by Roche in October 2006. Innovative pharmaceutical products and services are developed and delivered. Chugai Pharmaceutical has completed 1 acquisition, including Renalys. Its chief executive, as recorded, is Tatsuro Kosaka. Its website chugai-pharm.co.jp draws about 181 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its legal entity is CHUGAI PHARMA USA, INC.
Company details
Chugai Pharmaceutical was founded in 1925 and is headquartered in Tokyo, Japan, within the pharmaceutical sector. Research and development efforts are centered on creating medications for various health needs. Operations include collaborative partnerships to combine expertise in treatment creation and delivery. Patient-centric approaches are emphasized, alongside sustainable healthcare practices. Contributions are made to scientific progress and global health initiatives through these activities.
- Headquarters Tokyo, Japan
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website chugai-pharm.co.jp
- Social LinkedIn X YouTube
- Acquired by Roche (Oct 2006)
- Legal Name Chugai Pharmaceutical Co., Ltd.
Apps and channels of Chugai Pharmaceutical
its YouTube channel 中外製薬 Chugai Pharmaceutical has 12.5K subscribers and 30 videos.
Videos from Chugai Pharmaceutical
The most watched videos on Chugai Pharmaceutical's YouTube channel, 中外製薬 Chugai Pharmaceutical (12.5K subscribers). Click a video to play it here.
More on 中外製薬 Chugai Pharmaceutical.
Investors in Chugai Pharmaceutical
Chugai Pharmaceutical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Roche.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Chugai Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Chugai Pharmaceutical
21 people are tracked at Chugai Pharmaceutical (7 in leadership, 10 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Tatsuro Kosaka | CEO & President | Leadership |
Osamu Okuda | Representative Director, President & CEO | Leadership |
Iwaaki Taniguchi | Director, EVP & CFO | Leadership |
Junichi Ebihara | Executive Vice President | Leadership |
Tsukasa Kusano | VP, Head of Clinical Development | Leadership |
Hitoshi Iikura | Director, Executive Vice President | Leadership |
Naoya Fujihara | VP, External Affairs Deptartment | Leadership |
Yoshiaki Ohashi | Board Member | Board & advisors |
Christoph Franz | Director | Board & advisors |
Kenichi Masuda | Board Member | Board & advisors |
Mariko Y Momoi | Director | Board & advisors |
Shigehiro Yamada | Director | Board & advisors |
Teresa A. Graham | Director | Board & advisors |
Fumio Tateishi | Director | Board & advisors |
Yumiko Waseda | Director | Board & advisors |
Hideo Teramoto | Director | Board & advisors |
Mami Yunoki | Director | Board & advisors |
Shinji Hidaka | EVP, Supervisory responsibility for Marketing & Sales | Team |
Paul Mignone | General Counsel | Team |
Vivian Mak | Finance And Accounting Manager | Team |
1 more people are available in the full profile.
Complete people profiles for Chugai Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Chugai Pharmaceutical
Chugai Pharmaceutical is a publicly listed company on the TSE with ticker symbol 4519 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Mar 1956
- Listed onTSE: 4519
- Listed entityChugai Pharmaceutical Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3519400000
- Share price6,040.00 JPY (-2.11% on the day) · 2026-10-14
- Market capitalisation10,154,357,336,426.00 JPY
- Price to earnings21.1
- EPS (diluted, trailing year)286.42 JPY
- Dividend yield3.45%
- Volume (last session)2,360,400
Financials of Chugai Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1,260.00B JPY | 434.01B JPY | 624.44B JPY |
| 2024 | 1,170.00B JPY | 387.32B JPY | 575.57B JPY |
| 2023 | 1,110.00B JPY | 325.47B JPY | 447.40B JPY |
| 2022 | 1,260.00B JPY | 374.43B JPY | 565.38B JPY |
| 2021 | 999.76B JPY | 303.00B JPY | 464.61B JPY |
Detailed financial statements for Chugai Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chugai Pharmaceutical
Chugai Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Renalys.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for renal diseases are developed and launched by Renalys. | renalys.com | Chuo, Japan | 2023 | Oct 2025 | $98.32M |
Complete acquisition details for Chugai Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Chugai Pharmaceutical
The website of Chugai Pharmaceutical (chugai-pharm.co.jp) receives about 180.8K visits a month and ranks #220,597 among all websites worldwide, #7,243 in Biotechnology and Pharmaceuticals.
- Monthly visits180.8K
▼ 6.8% vs previous month
- Unique visitors129.6K
per month
- Global rank#220,597
among all websites
- Category rank#7,243
Health · Biotechnology and Pharmaceuticals
- Bounce rate65%
- Pages per visit2.3
- Average visit1 min 53 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Chugai Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astellas.com | 100% | 170.7K | #288,207 | View details | |
daiichisankyo.co.jp | daiichisankyo.co.jp | 100% | #309,295 | – | |
pfizer.co.jp | pfizer.co.jp | 93% | #843,262 | – | |
eisai.co.jp | eisai.co.jp | 93% | #356,397 | – | |
| mt-pharma.co.jp | 92% | 18.4K | #158,674 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Chugai Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chugai Pharmaceutical
Complete news archive for Chugai Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chugai Pharmaceutical
Chugai Pharmaceutical was founded in 1925.
Chugai Pharmaceutical is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Tatsuro Kosaka is the CEO of Chugai Pharmaceutical, as recorded in our data.
Annual revenue of Chugai Pharmaceutical is $8.04B as on Dec 31, 2025.
Chugai Pharmaceutical was founded in 1925 and is headquartered in Tokyo, Japan, within the pharmaceutical sector. Research and development efforts are centered on creating medications for various health needs. Operations include collaborative partnerships to combine expertise in treatment creation and delivery. Patient-centric approaches are emphasized, alongside sustainable healthcare practices. Contributions are made to scientific progress and global health initiatives through these activities.
Yes, Chugai Pharmaceutical is publicly traded on TSE under the ticker symbol 4519.
Chugai Pharmaceutical has made 1 acquisition, including Renalys.
Chugai Pharmaceutical has 1 investor. Key investors include Roche.
Chugai Pharmaceutical operates through Chugai Pharma Usa, Inc..
Yes. Chugai Pharmaceutical was acquired by Roche in October 2006.
The website of Chugai Pharmaceutical receives about 181 thousand visits a month and ranks #220,597 among all websites worldwide.